- |||||||||| ABBV-992 / AbbVie, ABBV-623 / AbbVie
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Adverse events: Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers (clinicaltrials.gov) - Feb 3, 2023 P1, N=5, Terminated, N=105 --> 5 | Trial completion date: May 2023 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: May 2023 --> Jan 2023; Strategic considerations
- |||||||||| ABBV-992 / AbbVie, ABBV-623 / AbbVie
Trial completion date, Trial primary completion date, Adverse events: Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers (clinicaltrials.gov) - Dec 12, 2022 P1, N=5, Active, not recruiting, N=105 --> 5 | Trial completion date: May 2023 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: May 2023 --> Jan 2023; Strategic considerations Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jan 2023 --> May 2023
- |||||||||| ABBV-992 / AbbVie, ABBV-623 / AbbVie
Enrollment closed, Enrollment change, Adverse events: Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers (clinicaltrials.gov) - Feb 8, 2022 P1, N=5, Active, not recruiting, Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jan 2023 --> May 2023 Recruiting --> Active, not recruiting | N=105 --> 5
|